Anemia Treatment and Its Clinical Implications in Patients Receiving Hemodialysis Hyporesponsive to Erythropoietin-Stimulating Agents [0.03%]
促红细胞生成素药物低反应性血液透析患者的贫血治疗及其临床意义
James B Wetmore,Julie Rouette,Anna Richards et al.
James B Wetmore et al.
Rationale & objective: Anemia, highly prevalent among patients receiving maintenance dialysis, may be associated with adverse outcomes. This study describes the patient characteristics, anemia treatment patterns, clinical...
Daratumumab for Treatment of Refractory Podocytopathy: A Case Report [0.03%]
达雷木单抗治疗难治性 podocytopathy 病例报告
Andreia Curto,Victor J Martinez Leon,Abdallah S Geara
Andreia Curto
Primary podocytopathies, manifesting as minimal change disease and primary focal and segmental glomerulosclerosis, previously had a debatable pathogenesis. However, with the recent discovery of antinephrin antibodies, these primary podocyto...
Case Reports
Kidney medicine. 2026 Jan 8;8(3):101253. DOI:10.1016/j.xkme.2026.101253 2026
Functional Analysis of a Novel Pathogenic Glycine Amidinotransferase Mutant in Hereditary Fanconi Syndrome [0.03%]
遗传性范可尼综合征致病新基因胍胺酸氨idine转移酶突变的功能研究
Shunsuke Takayanagi,Keita P Mori,Youngna Kang et al.
Shunsuke Takayanagi et al.
The mutant glycine amidinotransferase (GATM) protein polymerizes into a characteristic crystal, resulting in mitochondrial dysfunction in proximal tubules and Fanconi syndrome with progressive kidney failure. We identified a novel hereditar...
Case Reports
Kidney medicine. 2026 Jan 14;8(3):101267. DOI:10.1016/j.xkme.2026.101267 2026
Mahtab Mashayekhi,Jonathan E Zuckerman,Jonathan Barratt et al.
Mahtab Mashayekhi et al.
C3 glomerulopathy (C3G) is characterized by prominent deposition of complement component C3 in the kidney glomeruli, leading to glomerular inflammation. C3G is a rare and complex pattern of injury caused by dysregulation of the alternative ...
Corrigendum to "New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases": [Kidney Medicine 7 (2025) 101133] [0.03%]
关于“成人原发性肾小球疾病的新型和新兴非免疫抑制药物治疗”的勘误声明：[肾脏医学7（2025）101133]
Vladimir Mushailov,Jai Radhakrishnan
Vladimir Mushailov
[This corrects the article DOI: 10.1016/j.xkme.2025.101133.]. © 2026 The Authors.
Published Erratum
Kidney medicine. 2026 Jan 30;8(3):101281. DOI:10.1016/j.xkme.2026.101281 2026
The Association of Urine Albumin to Protein Ratio With Kidney Disease Progression [0.03%]
尿白蛋白与蛋白质比值与肾脏病进展的关系
Reed Jaworski,Afolarin Amodu,Jing Liu et al.
Reed Jaworski et al.
Incremental Hemodialysis Practices and Impact on Survival: Systematic Review and Meta-Analysis [0.03%]
增量血液透析的实践及对生存率的影响：系统综述和.meta.分析
Adil M Hazara,Abdullah Abdullah,Victoria Allgar et al.
Adil M Hazara et al.
Background: Starting hemodialysis (HD) incrementally may help reduce the burden of treatment in patients with established kidney failure. A systematic review has been conducted to describe variations in the practice of in...
Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials [0.03%]
钠葡萄糖共转运蛋白2抑制剂与急性肾损伤风险的系统评价和 meta 分析：随机对照试验证据
Yu-Cheng Chiang,Dao-Fu Dai,Yi-Wen Chiu et al.
Yu-Cheng Chiang et al.
Rationale & objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide cardiovascular and renal benefits in individuals with or without type 2 diabetes. This systematic review and meta-analysis investigated th...
Stratifying Hepatic Fat in Hemodialysis: The Role of Phenotype and Anemia Therapy [0.03%]
血透患者肝脂肪蓄积的分层分析：表型与治疗的作用
Hiroki Ito,Takefumi Mori
Hiroki Ito
Open-label Randomized Controlled Trial of Controlled-release Formulation Budesonide in Indian Proteinuric IgA Nephropathy Patients [0.03%]
印度蛋白尿IgA肾病患者使用布地奈德缓释制剂的开放性随机对照试验
Pradeep Das,Arpita Ray Chaudhury,Saugat Dasgupta et al.
Pradeep Das et al.
Introduction: IgA nephropathy (IgAN) in India is reported to have an onset at a younger age with faster progression to kidney failure requiring replacement therapy, where safe immunosuppression may improve the outcome. Th...